Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
about
Follicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal ModelsCell-surface central nervous system autoantibodies: clinical relevance and emerging paradigmsTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesNeuromyelitis optica spectrum disorders associated with other autoimmune diseases.Corticospinal tract integrity measured using transcranial magnetic stimulation and magnetic resonance imaging in neuromyelitis optica and multiple sclerosis.Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat modelFatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosisLow levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability.Neuromyelitis optica IgG causes placental inflammation and fetal death.Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literaturePredictors of recurrence following an initial episode of transverse myelitisThe pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.Neuromyelitis optica spectrum disorders without and with autoimmune diseases.Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patientsInhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in childrenProtocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica.Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelinesHigher frequency of brain abnormalities in neuromyelitis optica spectrum disorder patients without primary Sjögren's syndrome.Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G.Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study.C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgGA clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort.Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The X-Linked Hypothesis of Brain Disorders: Can Gender Ratios Tell Us Anything About Cellular Etiology of Neurodegenerative and Psychiatric Diseases?Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids.Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.Neuromyelitis optica and pregnancy.Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder.Acute Clinical Worsening after Steroid Administration in Cervical Myelitis May Reveal a Subdural Arteriovenous Fistula.The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis.Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica.The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases.
P2860
Q26795577-84E53A02-E874-4293-8CAD-B97582FE15E4Q27006941-2C3BF0F3-1D3F-4883-8A4E-9869432D2DECQ28245749-03397193-68CF-43BF-9CDF-6ED98D57E644Q30832651-D5C3C508-1516-4669-B155-AABAC99CAE54Q30945628-553EAC64-2CC9-42E7-88CA-36A0B52C4F9AQ33734731-6F220099-42D4-4478-8958-43A067A25FC9Q34142474-89EFF9AA-B4B0-46AB-A78F-99D463BCC26CQ34150992-73AED8A5-A5CC-40E8-9BCC-802B365B7F47Q34166367-26CB93C2-783B-4418-8DD4-54330B5057B4Q34168084-F9C36B15-A350-4AE9-A821-979072F8B489Q34320394-922A0253-CD8B-4B24-973C-5EFDD4220AB6Q34368590-BF6F5963-E89F-4ECE-9BC8-F3931BA0836CQ34392387-D3530E9A-05AC-4AF6-86DD-2490A7FB9993Q34529121-10B9E124-814B-40F6-B04A-C68727B58C91Q34538605-DF7F88FA-D27D-4E3F-B0D0-904AF7A8C86EQ34687502-79026A10-A226-45F8-8241-5A15FB897B4CQ35013113-9D1C8934-462A-4B3B-9E55-D5D32101D5D7Q35179839-A02C4C72-1684-4E45-AD45-B5FCCF2BE608Q35675625-89CABC1C-FF83-47A8-B67C-DE0326620016Q36058632-66D466C1-D98D-43C4-B1E5-D0655B538B68Q36359371-52EF10BF-2F3A-4CDE-8AE9-5ED47BA815F0Q36696590-C63579B6-3488-4EE5-9A04-9338B95A0CE0Q37312209-8209137C-E146-4E12-9838-483305F09DB4Q37425235-EF4769A6-EE42-4CE1-A3D4-5F9545AF0459Q37539041-A456F551-38F3-4F3D-AB37-BF12BDCD7990Q37567603-9E1B2928-E252-4309-9594-952848747213Q37615906-278B88CF-0B5F-4B7C-ADDA-53FF4257CB4AQ37638498-5F8A987A-CC9C-406A-A956-82D15D9465EDQ37712153-931FC351-0261-495C-8901-38C115D440D8Q38152822-ECA2A0B5-1ADB-4E40-B609-3A9502850B66Q38172961-2ECA834D-516D-4992-8133-D45713714950Q38238242-FDE1C972-C834-455F-A18F-D9C655DA28E5Q38774697-B34E8039-F952-423E-B1BD-7B27F5E32E04Q38816869-0126250D-9811-4B65-AD28-458050C650DDQ38866313-F1B6C37B-BA73-458E-99E5-808F659A97CFQ38870861-1A5EE8DA-997C-40A2-B1A5-AB226A046B12Q40422556-B8816262-B224-4249-BDE2-67A38CD5EF32Q40920201-492B4401-9169-4D0B-82AD-FFD421940C39Q42143005-99643FBF-EF99-491F-A959-7F71F4FCD5C5Q42232012-88C11769-3EBC-4FD4-9DCB-5A864E66CEE0
P2860
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
@ast
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
@en
type
label
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
@ast
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
@en
prefLabel
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
@ast
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
@en
P2093
P2860
P50
P356
P1476
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders
@en
P2093
Kazuo Fujihara
Liene Elsone
P2860
P304
P356
10.1136/JNNP-2012-302310
P407
P577
2012-11-10T00:00:00Z